专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004050684A2 METHODS FOR IMPROVING SECONDARY METABOLITE PRODUCTION IN FUNGI 审中-公开
标题翻译：改善真菌中次生代谢产物的方法
公开(公告)号：WO2004050684A2
公开(公告)日：2004-06-17
申请号：PCT/US0338528
申请日：2003-12-03
申请人： MICROBIA INC , BUSBY ROBERT , CALI BRIAN M , HECHT PETER , HOLTZMAN DOUGLAS , MADDEN KEVIN T , MAXON MARY , MILNE TODD G , NORMAN THEA , ROYER JOHN C , SILVA JEFFREY C , SUMMERS ERIC F , ZHANG LIXIN , MAYORGA MARIA , FEIBELMAN TOBY , DOTEN REED
发明人： BUSBY ROBERT , CALI BRIAN M , HECHT PETER , HOLTZMAN DOUGLAS , MADDEN KEVIN T , MAXON MARY , MILNE TODD G , NORMAN THEA , ROYER JOHN C , SILVA JEFFREY C , SUMMERS ERIC F , ZHANG LIXIN , MAYORGA MARIA , FEIBELMAN TOBY , DOTEN REED
IPC分类号： C07K20060101 , C12N1/16 , C12P15/00 , C12P17/04 , C12P17/06 , C12P19/62 , C07K
CPC分类号： C12N15/80 , C12P15/00 , C12P17/04 , C12P17/06 , C12P19/62 , C12P37/00
摘要： Methods for improving secondary metabolite production by modulating certain genes involved in secondary metabolite production, including genes encoding CreA, AreA, GanB, Gna3, FadA, Gna1, Gpa1, RfeH, An09, PacC, Lys14, LovU, Ste7, Pde2, Nc1, Vps34 and fungal homologs thereof.
摘要翻译：包括编码CreA，AreA，GanB，Gna3，FadA，Gna1，Gpa1，RfeH，An09，PacC，Lys14，LovU，Ste7，Pde2，Nc1，Vps34等基因的调节某些参与次级代谢产物的基因的次级代谢产物生成方法及其真菌同系物。

2. 发明申请

WO02057456A3 REGULATORS OF FUNGAL GENE EXPRESSION 审中-公开
标题翻译：真菌基因表达调控因子
公开(公告)号：WO02057456A3
公开(公告)日：2003-05-01
申请号：PCT/US0149911
申请日：2001-12-24
申请人： MICROBIA , CALI BRIAN M , MADDEN KEVIN T , MILNE TODD G , ZHANG LIXIN , SILVA JEFFREY C , TRUEHEART JOSHUA , HOLTZMAN DOUGLAS , SHERMAN AMIR
发明人： CALI BRIAN M , MADDEN KEVIN T , MILNE TODD G , ZHANG LIXIN , SILVA JEFFREY C , TRUEHEART JOSHUA , HOLTZMAN DOUGLAS , SHERMAN AMIR
IPC分类号： C12N15/09 , C07K14/37 , C07K14/38 , C07K14/385 , C12N15/31 , C07K16/14 , C12N15/62 , C12P7/62 , C12P37/00 , C12Q1/68
CPC分类号： C07K14/385 , C07K14/38
摘要： The invention relates to regulators of fungal gene expression and their use in commercial and medical applications. More particularly, the invention relates to regulators of fungal genes involved in production of enzymes, secondary metabolites and other useful products, as well as to regulators of genes involved in fungal invasion. The invention provides novel regulators of fungal gene expression, and methods for using regulator genes in commercial and medical applications.
摘要翻译：本发明涉及真菌基因表达的调节剂及其在商业和医学应用中的用途。更具体地，本发明涉及涉及酶，次生代谢物和其它有用产物的生产的真菌基因调节剂，以及参与真菌侵袭的基因的调节剂。本发明提供了真菌基因表达的新型调节剂，以及在商业和医学应用中使用调节基因的方法。

3. 发明申请

WO2004044176A8 ADENOVIRAL VECTOR VACCINE 审中-公开
公开(公告)号：WO2004044176A8
公开(公告)日：2005-09-09
申请号：PCT/US0336237
申请日：2003-11-12
申请人： DEISSEROTH ALBERT B , ZHANG LIXIN
发明人： DEISSEROTH ALBERT B , ZHANG LIXIN
IPC分类号： C07K14/025 , C12N15/64 , A61K31/70
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/575 , C07K14/005 , C07K14/70575 , C07K14/70578 , C07K2319/02 , C07K2319/40 , C07K2319/74 , C12N15/86 , C12N2710/10343 , C12N2710/10371 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071
摘要： Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
摘要翻译：提供用于产生对抗原的免疫应答的腺病毒载体。载体包含编码可分泌多肽的转录单元，该多肽包含在CD40配体上游的肿瘤抗原上游的分泌信号序列，其缺失所有或基本上所有的跨膜结构域再现CD40L可分泌。还提供了通过施用有效量的本发明载体产生针对表达肿瘤抗原的细胞的免疫应答的方法。还提供了通过施用有效量的本发明载体产生针对表达个体肿瘤抗原的癌症的免疫应答的方法。还提供了通过施用有效量的本发明的针对HPV的E6或E7蛋白的本发明载体来产生人乳头瘤病毒（HPV）感染免疫的方法。产生的免疫力是长期的。

4. 发明申请

WO2011033265A8 PHARMACEUTICAL COMPOUNDS 审中-公开
标题翻译：药物化合物
公开(公告)号：WO2011033265A8
公开(公告)日：2011-07-14
申请号：PCT/GB2010001746
申请日：2010-09-17
申请人： ALMAC DISCOVERY LTD , BELL MARK PETER , O'DOWD COLIN RODERICK , ZHANG LIXIN , TREVITT GRAHAM PETER , HARRISON TIMOTHY , BHATTACHARYYA SUMITA , ROUNTREE JAMES SAMUEL SHANE , BURKAMP FRANK , PRICE STEPHEN , MACLEOD CALUM , ELLIOTT RICHARD LEONARD , SMITH PHILLIP , BLENCH TOBY JONATHAN , DYKE HAZEL JOAN
发明人： BELL MARK PETER , O'DOWD COLIN RODERICK , ZHANG LIXIN , TREVITT GRAHAM PETER , HARRISON TIMOTHY , BHATTACHARYYA SUMITA , ROUNTREE JAMES SAMUEL SHANE , BURKAMP FRANK , PRICE STEPHEN , MACLEOD CALUM , ELLIOTT RICHARD LEONARD , SMITH PHILLIP , BLENCH TOBY JONATHAN , DYKE HAZEL JOAN
IPC分类号： C07D311/26 , A61K31/353 , A61K31/4155 , A61K31/4162 , A61K31/436 , A61P35/00 , C07D407/04 , C07D491/04
CPC分类号： C07D311/26 , C07D407/04 , C07D491/04
摘要： The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
摘要翻译：本发明涉及作为丝氨酸 - 苏氨酸激酶AKT抑制剂的特定活性的一系列化合物。还提供了包含其的药物组合物以及用于治疗癌症的方法。

5. 发明申请

WO2011000748A3 RESOURCE ALLOCATION IN VIRTUALIZED ENVIRONMENTS 审中-公开
标题翻译：虚拟化环境中的资源分配
公开(公告)号：WO2011000748A3
公开(公告)日：2011-02-24
申请号：PCT/EP2010058884
申请日：2010-06-23
申请人： IBM , IBM UK , ELNOZAHY ELMOOTAZBELLAH NABIL , SPEIGHT WILLIAM EVAN , ZHANG LIXIN , RAJAMONY RAMAKRISHNAN
发明人： ELNOZAHY ELMOOTAZBELLAH NABIL , SPEIGHT WILLIAM EVAN , ZHANG LIXIN , RAJAMONY RAMAKRISHNAN
IPC分类号： G06F9/455 , G06F9/50
CPC分类号： G06F9/50 , G06F9/455 , G06F9/5005 , G06F9/5011 , G06F9/5061 , G06F13/00
摘要： A method, a system, an apparatus, and a computer program product for allocating resources of one or more shared devices to one or more partitions of a virtualization environment within a data processing system. At least one user defined resource assignment is received for one or more devices associated with the data processing system. One or more registers, associated with the one or more partitions are dynamically set to execute the at least one resource assignment, whereby the at least one resource assignment enables a user defined quantitative measure (number and/or percentage) of devices to operate when the one or more transactions are executed via the partition. The system enables the one or more devices to execute one or more transactions at a bandwidth/capacity that is less than or equal to the user defined resource assignment and minimizes performance interference among partitions.
摘要翻译：一种用于将一个或多个共享设备的资源分配给数据处理系统内的虚拟化环境的一个或多个分区的方法，系统，装置和计算机程序产品。接收与数据处理系统相关联的一个或多个设备的至少一个用户定义的资源分配。与所述一个或多个分区相关联的一个或多个寄存器被动态地设置为执行所述至少一个资源分配，由此所述至少一个资源分配能够使用户定义的定量量度（数量和/或百分比）一个或多个事务通过分区执行。该系统使得一个或多个设备能够以小于或等于用户定义的资源分配的带宽/容量执行一个或多个事务并且使分区之间的性能干扰最小化。

6. 发明申请

WO2012127287A2 COMPOSITIONS AND METHODS FOR TREATING MULTI-DRUG RESISTANT MALARIA 审中-公开
标题翻译：用于治疗多药耐药性疟疾的组合物和方法
公开(公告)号：WO2012127287A2
公开(公告)日：2012-09-27
申请号：PCT/IB2011053962
申请日：2011-09-10
申请人： FEBRIS BIO TECH LTD , SMITH GARTH SELWYN , ZHANG LIXIN , DAI HUANQIN
发明人： SMITH GARTH SELWYN , ZHANG LIXIN , DAI HUANQIN
IPC分类号： A61K36/28 , A23L27/30
CPC分类号： A61K36/28 , A61K31/365 , A61K31/366 , A61K31/385 , A61K31/704 , A61K36/18 , A61K36/42 , A61K2300/00
摘要： A method is provided for treating an individual for a malarial infection, in particular drug-resistant species of Plasmodium, including administering to the individual in need of such treatment a composition comprising an extract containing an effective amount of one or more anti-malarial di- or tri-terpene compounds. Potent and effective extracts containing the anti-malarial compounds can be derived from Luo Han fruit and Stevia leaves, including combinations of the same, for the purpose of treating and preventing malaria in an inexpensive manner from readily available commodities. In one embodiment, the composition is administered orally in a solid or liquid ingestible form.
摘要翻译：提供了一种用于治疗个体为疟疾感染的方法，特别是疟原虫的耐药品种，包括向需要这种治疗的个体施用组合物，该组合物包含含有有效量的一种或多种抗疟疾二 - 或三萜烯化合物。含有抗疟疾化合物的强力有效提取物可以从罗汉果实和甜叶菊叶中得到，包括其组合，用于以便宜的商品廉价地治疗和预防疟疾。在一个实施方案中，组合物以固体或液体可摄取的形式口服施用。

7. 发明申请

WO2011077098A9 INHIBITORS OF AKT ACTIVITY 审中-公开
标题翻译： AKT活动的抑制剂
公开(公告)号：WO2011077098A9
公开(公告)日：2012-04-19
申请号：PCT/GB2010002329
申请日：2010-12-23
申请人： ALMAC DISCOVERY LTD , ZHANG LIXIN , TREVITT GRAHAM PETER , MIEL HUGHES , BURKAMP FRANK , HARRISON TIMOTHY , WILKINSON ANDREW JOHN , FABRITIUS CHARLES-HENRY
发明人： ZHANG LIXIN , TREVITT GRAHAM PETER , MIEL HUGHES , BURKAMP FRANK , HARRISON TIMOTHY , WILKINSON ANDREW JOHN , FABRITIUS CHARLES-HENRY
IPC分类号： C07D471/04 , A61K31/4741 , A61P35/00 , C07D498/04 , C07D498/14
CPC分类号： C07D498/04 , C07D471/04 , C07D498/14
摘要： The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
摘要翻译：本发明涉及作为丝氨酸 - 苏氨酸激酶AKT抑制剂的特定活性的一系列化合物。还提供了包含其的药物组合物以及用于治疗癌症的方法。

8. 发明申请

WO2010090942A2 SPAR HULL BELLY STRAKE DESIGN AND INSTALLATION METHOD 审中-公开
标题翻译： SPAR HULL BELLY STRAKE设计和安装方法
公开(公告)号：WO2010090942A2
公开(公告)日：2010-08-12
申请号：PCT/US2010022364
申请日：2010-01-28
申请人： TECHNIP FRANCE , LUO MICHAEL Y H , MOHR HARVEY O , ZHANG LIXIN
发明人： LUO MICHAEL Y H , MOHR HARVEY O , ZHANG LIXIN
IPC分类号： B63B22/02 , B63B35/44 , B63B39/00 , B63B39/06
CPC分类号： B63B39/005 , B63B1/048 , B63B35/4406 , B63B2035/442
摘要： A spar hull for a floating vessel can include a hard tank having a belly portion, a fixed strake coupled to the outer surface of the tank and a folding strake coupled to the belly portion of the tank, the folding strake having one or more strake panels and one or more support frames. A method for installing folding belly strakes on a spar hull may include providing a floating spar hull having a hard tank with a belly side, rotating the spar so that the belly side is in a first workable position, coupling at least one folding strake to the belly side of the spar, and coupling the strake in a folded position for transport. The method may include positioning the spar hull offshore in a transport position, upending the spar hull, unfolding the strake, fixing the strake in the unfolded position and installing the spar hull.
摘要翻译：用于浮动船只的翼梁可以包括具有腹部的硬罐，耦合到罐的外表面的固定板条和耦合到罐的腹部的折叠板，折叠板具有一个或多个板条板和一个或多个支撑框架。用于在翼梁上安装折叠式腹板的方法可以包括：提供具有带有腹部侧面的硬罐的浮动翼梁，旋转翼梁使得腹部侧处于第一可操作位置，将至少一个折叠板连接到翼梁的腹部侧面，并将平台连接在折叠位置以便运输。该方法可以包括将桨叶船体近海定位在运输位置，从而升高翼梁船体，展开船形板，将船板固定在展开位置并安装翼梁船体。

9. 发明申请

WO2005051303A3 SCREENING FOR SYNERGISTIC COMPOUNDS 审中-公开
标题翻译：筛选合成化合物
公开(公告)号：WO2005051303A3
公开(公告)日：2006-12-21
申请号：PCT/US2004039086
申请日：2004-11-19
申请人： ZHANG LIXIN
发明人： ZHANG LIXIN
IPC分类号： A61K31/00 , A61K20060101 , A61K31/70
CPC分类号： A61K31/00 , A61K31/496 , A61K31/70 , G01N33/94 , A61K2300/00
摘要： This invention provides a powerful systematic approach to discovering next generation of chemical compounds or formulation that acts synergistically with the low dosage of known drugs. Existing drug or dropped drug candidate is selected. Then a library of either natural products or synthetic chemicals (pure or combinatorial) including macromolecules like nucleic acids and proteins is created. A functional assay including biochemical, cell based assays, animal models or clinical treatments are established, and a sub-optimal dose (10 % - 40 % of the maximum activity) of the selected drug is determined. Under this condition, the library at different titration would be screened in a high throughput manner that should give a 0.1 % to 1 % hit rate. The synergistic co-drug hit should generate 70 % - 100 % of the maximum activity by combination with the sub-optimal concentration of existing drug. Finally, the co-drug hits would be purified and identified. The co-drug could be a pure synthetic molecule, a compound from a combinatorial synthetic library or a mixture from nature or synthetic resources.
摘要翻译：本发明提供了一种强大的系统方法来发现与低剂量的已知药物协同作用的下一代化合物或制剂。选择现有药物或药物候选药物。然后，创建了包括大分子如核酸和蛋白质的天然产物或合成化学品（纯或组合）的文库。建立了包括生物化学，基于细胞的测定，动物模型或临床治疗的功能测定，并确定所选药物的次优剂量（最大活性的10％-40％）。在这种条件下，不同滴定的文库将以高通量的方式进行筛选，这样可以获得0.1％至1％的命中率。通过与现有药物的次优浓度组合，协同共同药物的攻击应产生70％〜100％的最大活性。最后，共同药物的命中将被纯化和鉴定。共同药物可以是纯合成分子，来自组合合成文库的化合物或来自天然或合成资源的混合物。

10. 发明申请

WO2004044176A2 ADENOVIRAL VECTOR VACCINE 审中-公开
标题翻译：腺病毒载体疫苗
公开(公告)号：WO2004044176A2
公开(公告)日：2004-05-27
申请号：PCT/US0336237
申请日：2003-11-12
申请人： DEISSEROTH ALBERT B , ZHANG LIXIN
发明人： DEISSEROTH ALBERT B , ZHANG LIXIN
IPC分类号： C07K14/025 , C12N
CPC分类号： A61K39/12 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/575 , C07K14/005 , C07K14/70575 , C07K14/70578 , C07K2319/02 , C07K2319/40 , C07K2319/74 , C12N15/86 , C12N2710/10343 , C12N2710/10371 , C12N2710/20022 , C12N2710/20034 , C12N2710/20071
摘要： Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
摘要翻译：提供了用于产生对抗原的免疫应答的腺病毒载体。所述载体包含编码可分泌多肽的转录单元，所述多肽包含CD40配体上游肿瘤抗原上游的分泌信号序列，其丢失全部或基本上全部跨膜结构域使CD40L可分泌。还提供了通过施用有效量的本发明载体产生针对表达肿瘤抗原的细胞的免疫应答的方法。进一步提供了通过施用有效量的本发明载体产生针对个体中表达肿瘤抗原的癌症的免疫应答的方法。还提供了通过施用有效量的编码HPV的E6或E7蛋白的本发明载体来产生对人乳头瘤病毒（HPV）感染的免疫力的方法。产生的免疫力是长期的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式